-
Abstract Number: 2566
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
-
Abstract Number: 2567
Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study
-
Abstract Number: 2568
Incidence of First Fracture in RA Is Increasing Faster Than the General Population
-
Abstract Number: 2569
A Novel Hyperferritinemia Screen to Aid Differentiation of Hyperinflammatory Disorders
-
Abstract Number: 2570
Comparison of the Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease (SJIA-LD) Cohort to CARRA Registry SJIA Patients Without Lung Disease
-
Abstract Number: 2571
Trajectories of Physical Function in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
-
Abstract Number: 2572
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
-
Abstract Number: 2573
Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (COSPIRIT-JIA): 16-week Results of a Multicentre, Randomised, Open-label Study
-
Abstract Number: 2574
Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children
-
Abstract Number: 2575
Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?
-
Abstract Number: 2576
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
-
Abstract Number: 2577
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
-
Abstract Number: 2578
Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
-
Abstract Number: 2579
Risk of End-Stage Renal Disease Among Patients with Lupus Nephritis on GLP-1 Receptor Agonists: A Retrospective Cohort Study
-
Abstract Number: 2580
Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
- « Previous Page
- 1
- …
- 171
- 172
- 173
- 174
- 175
- …
- 181
- Next Page »